Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Lancet Gastroenterol Hepatol. 2021 Oct 22;6(12):1002–1014. doi: 10.1016/S2468-1253(21)00312-5

Figure 4.

Figure 4.

Comparative efficacy of biologic agents for maintenance of clinical remission in patients with moderate-to-severe Crohn’s disease using network meta-analysis, expressed as odds ratios with 95% confidence intervals. Comparisons read from left-to-right; odds ratios for comparisons in the cell in common between column- and row-defining treatment. For maintenance of clinical remission, odds ratio >1 favors row-defining treatment.